Tang X B, Hobom G, Luo D
Department of Medical Microbiology and Infectious Diseases, University of Alberta, Edmonton, Canada.
J Med Virol. 1994 Apr;42(4):385-95. doi: 10.1002/jmv.1890420411.
Short catalytic RNAs with inherent, specific endoribonuclease activity, called ribozymes, have recently been shown to exist in nature. According to the structural models artificial ribozymes have been designed that can potentially hydrolyse any chosen target RNA sequence in trans at a specific site. We have constructed and characterized in vitro hammerhead and hairpin ribozymes designed to cleave viral RNA segment 5 of influenza A virus. Both ribozymes were functional under optimal in vitro conditions, but quantitative measurements indicate that the hammerhead ribozyme is considerably more efficient at this target site than the hairpin ribozyme. Mg2+ dependent hammerhead ribozyme-mediated cleavage reactions were enhanced at higher temperature and in presence of spermidine, but catalytic activities were retained also in cellular extract S-100 or nuclear extracts at physiological temperatures. Recombinant plasmids derived from transfection vector pSV2-neo were engineered to allow the expression of specific ribozymes under the control of SV40 early promoter or SV40 early+ late promoters. These plasmids were introduced by transfection into COS cells, and their expression and enzymatic activities were analyzed in stable cell lines after selection of neomycin-resistance. Several permanent ribozyme-expressing clones were established and characterized: ribozyme coding DNA sequences and synthesis of ribozyme RNA molecules in the transfected cells were determined and monitored by polymerase chain reactions. It was found that the highest levels (up to 70-80%) of resistance to influenza A virus strain X-31 super-infection was observed in COS cells transfected with plasmids containing SV40 early or SV40 early+late promoters coinciding with relatively high and constitutive rates of ribozyme expression. These results suggest the feasibility of developing ribozymes designed against influenza virus to achieve therapeutic value.
具有内在特异性内切核糖核酸酶活性的短催化性RNA,即核酶,最近已被证明存在于自然界。根据结构模型,人们设计出了人工核酶,它们有可能在特定位点对任何选定的靶RNA序列进行反式水解。我们构建并表征了体外锤头状核酶和发夹状核酶,它们被设计用于切割甲型流感病毒的病毒RNA片段5。两种核酶在最佳体外条件下均有功能,但定量测量表明,在该靶位点,锤头状核酶比发夹状核酶效率高得多。依赖Mg2+的锤头状核酶介导的切割反应在较高温度和亚精胺存在下会增强,但在生理温度下,细胞提取物S-100或核提取物中也保留了催化活性。对源自转染载体pSV2-neo的重组质粒进行改造,使其能在SV40早期启动子或SV40早期+晚期启动子的控制下表达特定核酶。通过转染将这些质粒导入COS细胞,并在选择新霉素抗性后,在稳定细胞系中分析它们的表达和酶活性。建立并表征了几个永久性表达核酶的克隆:通过聚合酶链反应确定并监测转染细胞中核酶编码DNA序列和核酶RNA分子的合成。结果发现,在用含有SV40早期或SV40早期+晚期启动子的质粒转染的COS细胞中,观察到对甲型流感病毒X-31株超感染的最高抗性水平(高达70-80%),这与相对较高且组成型的核酶表达率一致。这些结果表明,开发针对流感病毒的核酶以实现治疗价值是可行的。